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Purpose: The goal of the present research was to study post-treatment changes in polypoidal choroidal vasculop-
athy (PCV) shown by optical coherence tomography (OCT).
Methods: The study included 12 patients with naive PCV. Photodynamic therapy and 3 consecutive intravitreal bev-
acizumab injections at 6-week intervals were given. Best corrected visual acuity, subretinal fluid (SRF), pigment 
epithelium detachment (PED), central macular thickness (CMT), and total macular volume (TMV) were measured 
before and after treatment as assessed by Stratus OCT3.
Results: After treatment, the SRF height decreased earlier than the PED height. The SRF diameter decreased with 
statistical significance. However, the PED diameter did not show a statistically significant improvement, persist-
ing at pre-treatment levels. Both CMT and TMV decreased significantly after treatment. 
Conclusions: After PCV treatment, SRF and PED stabilized, as shown by OCT. However, the PED treatment re-
sponse was both delayed and refractory compared to the SRF response. The small change in post-treatment 
PED diameter may suggest the possibility of PCV recurrence. 
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Polypoidal choroidal vasculopathy (PCV) is a clinical dis-
ease entity featuring a branching vascular network terminat-
ing in polypoidal lesions [1-8]. PCV pathophysiology is not 
fully understood [9] but many inner choroidal vessel abnor-
malities have been reported. PCV clinical findings include 
elevated orange-red lesions on fundus photography and char-
acteristic polypoidal lesions on indocyanine green angiog-
raphy (ICG). The polypoidal lesions apparently correspond 
to the lesions on fundus photography. 
ICG is an essential test for the diagnosis of PCV; on ICG, 
branching network vessels and terminating polyps can be 
identified [10,11]. However, ICG is an invasive technique in-
volving an intravenous indocyanine green dye injection. 
Optical coherence tomography (OCT) is both non-invasive 
and supportive when used to diagnose PCV and can monitor 
changes in various retinal disease states. An OCT image of a 
PCV eye shows a moderate-to-high reflective polypoidal le-
sion, 2 reflective retinal pigment epithelium layer lines 
(termed the double-layer line), subretinal fluid (SRF), and 
pigment epithelium detachment (PED). Polypoidal lesions 
and dilated network vessels have been detected in various 
retinal areas of PCV patients, and can be distributed in the 
subfoveal [12,13],
 juxtafoveal, or extrafoveal regions [14]. 
PCV treatment methods include laser photocoagulation 
[15-17], photodynamic therapy (PDT) [18-24], and use of 
anti-vascular endothelial growth factor (anti-VEGF) drugs 
such as bevacizumab or ranibizumab. In a study regarding 
the long-term results of PDT treatment for PCV, Akaza et al. 
[18] found a high incidence of polypoidal lesion recurrence 
and a frequent need for additional treatment. To address these 
problems, many authors have explored anti-VEGF treat-
ments for PCV patients. JB Chae, et al. Polypoidal Choroidal Vasculopathy
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Fig. 1. Heights and diameters of pigment epithelium detachment (PED) and subretinal fluid (SRF). The same scan direction was used at all fol-
low-up visits to yield PED data (A) and SRF information (B).
Table 1. Characteristics of the 12 polypoidal choroidal 
vasculopathy patients
Characteristics Data
Male/Female 8 (67)/4 (33)
Age (yr)    69 ± 6.45
Location of polyp Subfoveal  4 (33)
Juxtafoveal  8 (67)
Number of PDT sessions   1.25 ± 0.452
Number of intravitreal 
bevacizumab injections
4.08 ± 1.83
Baseline BCVA (logMAR)    0.3 ± 0.23
Twelve-month BCVA (logMAR) 0.38 ± 0.14
Data are presented as number (%).
PDT = photodynamic therapy; BCVA = best corrected visual 
acuity; logMAR = logarithm of the minimum angle of resolution.
Many previous studies have assessed follow-up PCV 
pathologic changes by ICG or fluorescein angiography (FA) 
[11]. However, to the best of our knowledge, no report has fo-
cused on OCT changes during follow-up after treatment. The 
authors of the present study hypothesized OCT could be used 
to explore features of subfoveal or juxtafoveal PCV located 
near the macula. The present study describes the follow-up 
changes observed by OCT after PDT/bevacizumab treatment 
for PCV.
Materials and Methods
The present study included 12 eyes of 12 PCV patients 
who underwent PDT and 3 consecutive intravitreal bevacizumab 
injections at 6-week-intervals, at the the Asan Medical 
Center, Seoul, Korea, from March 2007 to December 2007. 
All examinations and investigations adhered to the tenets of 
the Declaration of Helsinki. This study was approved by the 
Asan Medical Center Institutional Review Board.
Inclusion criteria were 1) symptom onset under 3 months; 
2) confirmed polyps and branching vascular networks as 
seen by ICG; 3) visible SRF or PED on OCT images; 4) visu-
al acuity above 20 / 200; 5) subfoveal (within the foveal avas-
cular zone [FAZ]) or juxtafoveal (within 1-119 μm from the 
FAZ) PCV lesion areas that could be followed-up using 
OCT; and 6) a follow-up period longer than 12 months. 
Exclusion criteria were 1) extrafoveal pathologic PCV that 
could not be examined by routine OCT scanning; 2) choroi-
dal neovascularization of any other origin such as high my-
opia, uveitis, or trauma; 3) a previous operation history (in 
the past 6 months); or, 4) a history of adverse side-effects to 
verteporfin or ICG dyes.
The best corrective visual acuity (BCVA) was measured 
and slit lamp examinations, fundus photography, ICG, and 
OCT were performed at baseline. After confirmation of PCV 
diagnosis, 3 consecutive intravitreal bevacizumab injections 
(1.25 mg/0.05 mL), at 6-week intervals, were given. One 
week after the first bevacizumab injection, PDT employing 
verteporfin, covering all possible polyps and branching net-
work vessels, was performed. The patients visited for fol-
low-up 1, 3, 6, 9, and 12 months after the first treatment. 
Each patient received BCVA measurement, slit lamp exami-
nation, and OCT on each visit. If there was evidence of re-
currence, ICG was repeated at the discretion of the attending 
clinician. If recurrence was evidenced by new polyps on 
ICG, decreased visual acuity (VA), or increasing SRF or PED, 
additional treatment (PDT or an intravitreal bevacizumab in-
jection) was administered. 
OCT images were acquired using Stratus OCT3 ver. 4.0.1 
(Carl Zeiss Meditec Inc, Dublin, CA, USA). Central macular 
thickness (CMT), total macular volume (TMV), and 
PED/SRF heights and diameters were measured. CMT and 
TMV values were calculated by the Stratus OCT program 
software. Standard OCT scans were obtained using foveae as 
fixation points. To permit comparison of changes in OCT 
findings, scanning directions were kept constant at all fol-
low-up visits, using a standard macular mapping protocol. 
Two investigators (JBC and JYL) independently measured 
SRF and PED heights and diameters using a Photoshop 
length-measuring program (Adobe Systems, San Jose, CA, 
USA) (Fig. 1).
BCVA measurements, heights and diameters of SRF/PED, 
and CMT and TMV data were compared between baseline, 
and 1, 3, 6, 9, and 12 months post treatment. Furthermore, 
the effects of additional treatments were analyzed. Statistical 
comparisons were made using the Wilcoxon signed rank 
test submodule of SPSS ver. 12.0 (SPSS Inc., Chicago, IL, 
USA).Korean J Ophthalmol Vol.25, No.2, 2011
100
A  B  C
D  E   F
G  H   I
Fig. 2. Polypoidal choroidal vasculopathy in the left eye of a woman 61 years of age. Fundus photography showed retinal hemorrhage (A). 
Indocyanine green angiography (ICG) revealed polyps and network vessels (B). An optical coherence tomography (OCT) transverse scan 
showed the polypoidal lesion (red arrow) and dome-shaped pigment epithelium detachment (PED) (yellow arrow) (C). After 6 months, the 
hemorrhage disappeared (D), and no active leakage was seen on fluorescein angiography (E). Follow-up ICG was not performed. OCT 
showed a decrease in PED height but a PED diameter persistently greater than normal (yellow arrow); subretinal fluid was absent (F). 
Twelve months later, there was no hemorrhagic lesion on fundus examination (G,H), however OCT showed persistence of the abnormally 
large PED diameter (I).
Results
Baseline characteristics and clinical data of the 12 patients 
are summarized in Table 1. The mean patient age was 69 
years. In 4 patients, polyps were located in the subfoveal 
area, and in the other 8 patients, polyps were located in the 
juxtafoveal area. In addition to the first 3 consecutive bev-
acizumab injections and the single PDT treatment, 2 patients 
received repeated PDT treatments whereas 5 patients were 
prescribed a single extra bevacizumab injection (Table 1). 
Figs. 2 and 3 provide information on 2 of the 12 patients. SRF 
and PED height change responses, as observed on OCT, 
showed different patterns (Fig. 4). Compared to baseline, 
SRF height decreased significantly at the 1-, 3-, 6-, 9-, and 
12-month follow-ups (p-values 0.008, 0.008, 0.012, 0.043, 
and 0.018, respectively). PED height also decreased with 
time, however treatment response was delayed. At the 1- and 
3-month follow-ups, PED heights showed no statistically 
significant decreases (p-values 0.138 and 0.109, re-
spectively). However, at the 6- and 9-month follow-ups, clin-
ically significant decreases in PED heights were observed 
(p-values 0.018 and 0.028, respectively). At the 12-month 
follow-up, PED height had increased and a tendency toward 
disease recurrence was observed.  
SRF and PED diameter changes, measured by OCT, are 
shown in Fig. 5. The SRF diameter decreased significantly at JB Chae, et al. Polypoidal Choroidal Vasculopathy
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Fig. 3. Polypoidal choroidal vasculopathy in the right eye of a 
man 61 years of age. An orange-red subretinal hemorrhage with
pigment epithelium detachment (PED) was observed on fundus 
photography (A). By indocyanine green angiography, a branch-
ing vascular network and polyps were observed (B). Optical co-
herence tomography showed 2 dome-shaped PED regions. The 
scanning direction was vertical (C). Three months after intra-
vitreal bevacizumab and photodynamic therapy, the PED re-
solved (D). However, remnant PED areas were observed at the 
9-month follow-up (red arrows) (E). 
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Fig. 4. Mean (± standard deviation) pigment epithelium detach-
ment (PED) and subretinal fluid (SRF) heights of 12 polypoidal cho-
roidal vasculopathy patients at baseline and all follow-ups. SRF 
height decreased at 1-,3-,6-,9- and 12-month follow-ups with clin-
ical significance. PED heights showed no statistically significant de-
creases at the 1- and 3-month follow-ups. However, at the 6- and 
9-month follow-ups, clinically significant decreases in the PED 
heights were observed.
Fig. 5. Pigment epithelium detachment (PED) and subretinal fluid 
(SRF) diameters at baseline and all follow-ups. The SRF diameter 
decreased with clinical and statistical significance at the 1-, 3-, and 
9-month follow-ups (p-values 0.005, 0.013, and 0.043 respectively). 
However, there was no significant decrease in PED diameter at any 
follow-up.Korean J Ophthalmol Vol.25, No.2, 2011
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Fig. 6. Central macular thickness (CMT) and total macular volume (TMV) of polypoidal choroidal vasculopathy patients at all follow-ups. 
Both CMT and TMV showed statistically significant decreases at all follow-up examinations.
Fig. 7. Best corrected visual acuity (BCVA) measurements at base-
line and at all follow-ups. BCVA showed a tendency toward im-
provement, however this was neither clinically nor statistically 
significant. logMAR = logarithm of the minimum angle of resolution.
the 1-, 3-, and 9-month follow-ups (p-values 0.005, 0.013, 
and 0.043, respectively). Notably, the PED diameter (as esti-
mated by OCT) did not show a statistically significant de-
crease at any follow-up. The PED diameter did not respond 
to even multiple PCV treatments, unlike what was noted 
when PED height was assessed. 
TMV and CMT measurements by OCT are shown in Fig. 
6. At all follow-up visits, clinically significant improvements 
were observed. Although the VA tended to improve, the VA 
data did not attain statistical significance (Fig. 7). 
Discussion 
PCV features a polypoidal lesion with a branching vas-
cular network accompanied by serous or hemorrhagic PED. 
Polyps and branching vascular networks detectable by ICG 
are specific findings that distinguish PCV from age-related 
macular degeneration (AMD). Many investigators have ex-
plored PCV pathology using various OCT instruments. In 
previous studies, PCV polypoidal lesions appeared as mod-
erate-to-highly reflective lesions on OCT. The branching 
vascular network vessels show as 2 distinct reflective lines; 
the phenomenon has been termed the ‘double-layer sign’. 
The reflective line components have not yet been identified 
by histopathology or microscopy [25]. Compared to AMD, 
the PED of PCV is more elevated, the lesion is dome-shaped, 
and fewer intraretinal cystic lesions are seen. PED is more 
prominent in PCV than in AMD. Although many OCT fea-
tures of PCV have been described, reports on follow-up 
changes observed by OCT are few in number. Therefore, the 
authors herein report PCV changes after treatment with 
PDT/intravitreal bevacizumab. In the present study, changes 
in PED/SRF heights and diameters were assessed. Treatment 
responses differed when PED and SRF were compared and 
SRF reduction preceded a fall in PED. However, the PED di-
ameter did not respond to PDT/intravitreal bevacizumab 
treatment. Both SRF diameter and height showed clinically 
significant decreases, but the PED diameter decreased only 
slightly, without clinical significance. In a recent study of 
PED pathophysiology, Tsujikawa and associates showed the 
branching vascular network and polyps were near or in the 
PED [26]. Lee et al. [27] reported PDT could not eliminate 
network vessels; new vessels were seen on ICG after PDT. 
The continuing enlarged PED diameter, except for a slight re-
duction at the 9-month follow-up observed in the present 
study, implies the possibility of branching vascular network 
persistence despite treatment. However, the present data also 
show OCT is valuable in monitoring patients for such re-
currence after treatment. 
In the present study, 7 out of 12 patients (58%) required ad-
ditional treatment, either PDT (2 cases) or a single intra-
ocular bevacizumab injection (5 cases) after the initial com-
bination treatment. Many investigators have reported PCV is 
both recurrent and refractory to treatment. Akaza et al. [18] 
reported a high PCV polypoidal lesion recurrence incidence JB Chae, et al. Polypoidal Choroidal Vasculopathy
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after PDT treatment in a study featuring 2 years of follow-up. 
Yamashiro et al. [28] found a 40% PCV recurrence rate after 
PDT [28].
 Thus, careful follow-up examinations are essential 
for PCV patients. OCT can conveniently monitor changes 
and identify when re-treatment is indicated. Although both 
ICG and FA can show PCV pathologic features more pre-
cisely than OCT, the former methods are both more invasive 
and inconvenient (for both patients and attending physicians) 
than OCT. 
Although the VA tended to improve after treatment at any 
point, the statistical significance was not attained. VA de-
creased slightly between the 9-month and 12-month fol-
low-ups. This may signify incipient PCV recurrence.
The present study had a size limitation (12 cases). However, 
the inclusion criteria were restricted to exclude selection 
bias. Only naïve patients with subfoveal or juxtafoveal PCV 
were recruited and examined. In such patients, OCT can 
monitor PCV lesions because the OCT scan length is 6 mm. 
Lesions were examined at all follow-up visits. However, fu-
ture studies with larger patient numbers are required. To the 
best of our knowledge, no report on OCT post-treatment fol-
low-up of PED or SRF has appeared. PED and SRF greatly 
affect VA and reflect PCV disease status. OCT permits PED 
and SRF changes to be compared. Furthermore, OCT can 
identify a need for re-treatment. 
In conclusion, despite treatment with PDT/intravitreal 
bevacizumab, PED regressed only incompletely and remnant 
PED bases were seen by OCT. PDT/bevacizumab treatment 
achieved SRF reduction and VA improvement. However, the 
persistence of the PED diameter enlargement observed on 
OCT despite treatment may suggest the possibility of PCV 
recurrence. The results from the present study indicate that 
PCV patients need careful follow-up. 
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